The CCL5/CCR5 axis contributes to the perineural invasion of human salivary adenoid cystic carcinoma

Oncology Reports

Volumn 31, Issue 2, 2014, Pages 800-806

  Shen, Zhiyuan ^a   Li, Tianyi ^a   Chen, Da ^a   Jia, Sen ^a   Yang, Xiangming ^a   Liang, Liang ^a   Chai, Juan ^a   Cheng, Xiaobing ^a   Yang, Xinjie ^a   Sun, Moyi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CCL5; CCR5; Perineural invasion; Salivary adenoid cystic carcinoma

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MARAVIROC; RANTES;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; PERINEURAL INVASION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SALIVARY ADENOID CYSTIC CARCINOMA; SALIVARY GLAND CARCINOMA; TUMOR INVASION;

CARCINOMA, ADENOID CYSTIC; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL5; CYCLOHEXANES; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PERIPHERAL NERVES; RECEPTORS, CCR5; SALIVARY GLAND NEOPLASMS; TRIAZOLES;

EID: 84892400108     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2920     Document Type: Article

References (32)

1. Liebig C, Ayala G, Wilks JA, Berger DH and Albo D: Perineural invasion in cancer: a review of the literature. Cancer 115: 3379-3391, 2009.
2. Barrett AW and Speight PM: Perineural invasion in adenoid cystic carcinoma of the salivary glands: a valid prognostic indicator? Oral Oncol 45: 936-940, 2009.
3. Johnston M, Yu E and Kim J: Perineural invasion and spread in head and neck cancer. Expert Rev Anticancer Ther 12: 359-371, 2012.
4. Poeschl EM, Pollheimer MJ, Kornprat P, et al : Perineural invasion: correlation with aggressive phenotype and independent prognostic variable in both colon and rectum cancer. J Clin Oncol 28: e358-e360, 2010.
5. Fromont G, Godet J, Pires C, Yacoub M, Dore B and Irani J: Biological significance of perineural invasion (PNI) in prostate cancer. Prostate 72: 542-548, 2012.
6. Sakurai J, Fujii Y and Shirotani M: Contraction induced by Clostridium perfringens alpha toxin in the isolated rat ileum. Toxicon 28: 411-418, 1990.
7. Cavel O, Shomron O, Shabtay A, et al: Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor. Cancer Res 72: 5733-5743, 2012.
8. Bapat AA, Hostetter G, von Hoff DD and Han H: Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer 11: 695-707, 2011.
9. Wang SW, Wu HH, Liu SC, et al: CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS One 7: e35101, 2012.
10. McIver SC, Loveland KL, Roman SD, Nixon B, Kitazawa R and McLaughlin EA: The chemokine CXCL12 and its receptor CXCR4 are implicated in human seminoma metastasis. Andrology 1: 517-529, 2013.
11. Zhu Q, Han X, Peng J, Qin H and Wang Y: The role of CXC chemokines and their receptors in the progression and treatment of tumors. J Mol Histol 43: 699-713, 2012.
12. Lv D, Zhang Y, Kim HJ, Zhang L and Ma X: CCL5 as a potential immunotherapeutic target in triple-negative breast cancer. Cell Mol Immunol 10: 303-310, 2013.
13. Bolin LM, Murray R, Lukacs NW, et al: Primary sensory neurons migrate in response to the chemokine RANTES. J Neuroimmunol 81: 49-57, 1998.
14. Vaday GG, Peehl DM, Kadam PA and Lawrence DM: Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66: 124-134, 2006.
15. Borczuk AC, Papanikolaou N, Toonkel RL, et al: Lung adenocarcinoma invasion in TGFßRII-deficient cells is mediated by CCL5/RANTES. Oncogene 27: 557-564, 2008.
16. - phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep 21: 1113-1121, 2009.
17. Swamydas M, Ricci K, Rego SL and Dréau D: Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases. Cell Adh Migr 7: 315-324, 2013.
18. Pinilla S, Alt E, Abdul Khalek FJ, et al: Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett 284: 80-85, 2009.
19. Velasco-Velázquez M, Jiao X, De La Fuente M, et al: CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 72: 3839-3850, 2012.
20. Demir IE, Friess H and Ceyhan GO: Nerve-cancer interactions in the stromal biology of pancreatic cancer. Front Physiol 3: 97, 2012.
21. Li LJ, Li Y, Wen YM, Liu H and Zhao HW: Clinical analysis of salivary gland tumor cases in West China in past 50 years. Oral Oncol 44: 187-192, 2008.
22. Yang X, Dai J, Li T, et al: Expression of EMMPRIN in adenoid cystic carcinoma of salivary glands: correlation with tumor progression and patients' prognosis. Oral Oncol 46: 755-760, 2010.
23. Sukhanova KY, Harhun MI, Bouryi VA and Gordienko DV: Mechanisms of [Ca2+]i elevation following P2X receptor activation in the guinea-pig small mesenteric artery myocytes. Pharmacol Rep 65: 152-163, 2013.
24. Yang X, Zhang P, Ma Q, et al: EMMPRIN contributes to the in vitro invasion of human salivary adenoid cystic carcinoma cells. Oncol Rep 27: 1123-1127, 2012.
25. Yang X, Zhang P, Ma Q, et al: EMMPRIN silencing inhibits proliferation and perineural invasion of human salivary adenoid cystic carcinoma cells in vitro and in vivo. Cancer Biol Ther 13: 85-91, 2012.
26. Bravo-Cordero JJ, Hodgson L and Condeelis J: Directed cell invasion and migration during metastasis. Curr Opin Cell Biol 24: 277-283, 2012.
27. Olson MF and Sahai E: The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 26: 273-287, 2009.
28. Detchokul S, Williams ED, Parker MW and Frauman AG: Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies. Br J Pharmacol: Jun 3, 2013 (Epub ahead of print). doi: 10.1111/bph.12260.
29. Dai H, Li R, Wheeler T, Ozen M, et al: Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum Pathol 38: 299-307, 2007.
30. Swanson BJ, McDermott KM, Singh PK, Eggers JP, Crocker PR, and Hollingsworth MA: MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Res 67: 10222-10229, 2007.
31. Sayana S and Khanlou H: Maraviroc: a new CCR5 antagonist. Expert Rev Anti Infect Ther 7: 9-19, 2009.
32. Kast RE: Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug. J Clin Pharm Ther 35: 657-663, 2010.